Stability Testing for FDA Approved KSHNO14 (Pyridostigmine Bromide Extend – Release Tablets)
| Location: | Maryland |
|---|---|
| Posted: | Jan 29, 2026 |
| Due: | Feb 19, 2026 |
| Agency: | DEPT OF DEFENSE |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | W911SR-26-S-ASPC |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Sources Sought (Original)
- Original Published Date: Jan 29, 2026 07:57 am EST
- Original Response Date: Feb 19, 2026 02:00 pm EST
- Inactive Policy: 15 days after response date
- Original Inactive Date: Mar 06, 2026
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: AC13 - NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; EXPERIMENTAL DEVELOPMENT
-
NAICS Code:
- 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
-
Place of Performance:
MD 21702USA
This Sources Sought notice is issued for market research purposes only to identify potential sources capable of supporting FDA compliant stability testing for FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablet for five (5) years at CRT and ten (10) years refrigerated, manufactured by Amneal Complex Research LLC and packaged in Blister Pack throughout the in-use period.
The government is specifically seeking information on vendors capable of assuming or supporting long term stability testing including continued continuity requirements associated with an existing ongoing stability study. This notice is not a solicitation for proposals, and no award will be made as a result of this notice.
CPE CBRN Medical CDP has an ongoing stability study in support of FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablets, the study includes multiyear stability testing including long term and refrigerated storage conditions with stability data.
The government is conducting market research to determine whether there are additional responsible sources capable of meeting the full scope of technical regulatory and continuity requirements associated with this effort.
- EDGEWOOD DIVISION 8456 BRIGADE STREET
- ABERDEEN PROVING GROU , MD 21010-5424
- USA
- Scott Hoffman
- scott.i.hoffman2.civ@army.mil
- Mea Johnson
- mea.n.johnson.civ@army.mil
- Jan 29, 2026 07:57 am ESTSources Sought (Original)
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business
See also
...Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood...- OTHER ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 5/31/2029
...neuroimaging research by enabling high-quality imaging directly at the bedside. Unlike conventional high... ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/09/2026
...beadchips will be implemented as part of a study conducted by the Center ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/12/2026
..., and tight-tolerance air temperature control systems for the conduct of research and ...
COMMERCE, DEPARTMENT OF
Bid Due: 6/12/2026